Korean J Endocr Surg.  2015 Mar;15(1):6-9. 10.16956/kaes.2015.15.1.6.

Updates in Familial Non-Medullary Thyroid Cancer

Affiliations
  • 1Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. gsyoon@amc.seoul.kr

Abstract

Familial non-medullary thyroid cancer (FNMTC) may be considered as a separate clinical entity with variable aggressive biologic behaviors on the basis of previously published studies. Therefore, a family history of NMTC should be carefully considered as a possible prognostic factor when endocrine surgeons set a plan regarding the extent of surgery, radioactive iodine treatment, and follow-up strategy for FNMTC patients.

Keyword

Familial non-medullary thyroid cancer; Family history

MeSH Terms

Humans
Iodine
Thyroid Neoplasms*
Iodine

Reference

References

1. Sippel RS, Caron NR, Clark OH. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up. World J Surg. 2007; 31:924–33.
Article
2. Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001; 86:5307–12.
Article
3. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994; 86:1600–8.
Article
4. Ron E, Kleinerman RA, LiVolsi VA, Fraumeni JF Jr. Familial nonmedullary thyroid cancer. Oncology. 1991; 48:309–11.
Article
5. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006; 16:181–6.
Article
6. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer. Thyroid. 1998; 8:857–8.
Article
7. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg. 1995; 130:892–7.
Article
8. Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer. 2003; 103:105–9.
Article
9. Maxwell EL, Hall FT, Freeman JL. Familial nonmedullary thyroid cancer: a matched-case control study. Laryngoscope. 2004; 114:2182–6.
Article
10. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 2011; 21:367–71.
Article
11. Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid. 2009; 19:1343–9.
Article
12. Khan A, Smellie J, Nutting C, Harrington K, Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid. 2010; 20:795–801.
Article
13. Hou P, Xing M. Absence of germline mutations in genes within the MAP kinase pathway in familial nonmedullary thyroid cancer. Cell Cycle. 2006; 5:2036–9.
Article
14. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005; 90:5747–53.
Article
15. Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, et al. Is familial nonmedullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000; 128:1043–50.
Article
16. Mazeh H, Benavidez J, Poehls JL, Youngwirth L, Chen H, Sippel RS. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 2012; 22:3–8.
Article
17. Hillenbrand A, Varhaug JE, Brauckhoff M, Pandev R, Haufe S, Dotzenrath C, et al. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg. 2010; 395:851–8.
18. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997; 7:107–13.
Article
19. Uchino S, Noguchi S, Kawamoto H, Yamashita H, Watanabe S, Yamashita H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002; 26:897–902.
Article
20. Lupoli G, Vitale G, Caraglia M, Fittipaldi MR, Abbruzzese A, Tagliaferri P, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999; 353:637–9.
Article
21. Uchino S, Noguchi S, Yamashita H, Murakami T, Watanabe S, Ogawa T, et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg. 2004; 28:1099–102.
Article
22. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, Shraga-Slutzky I, Weinstein R, Lazar L, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011; 21:43–8.
Article
23. Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009; 145:100–5.
Article
24. Ito Y, Fukushima M, Yabuta T, Inoue H, Uruno T, Kihara M, et al. Prevalence and prognosis of familial follicular thyroid carcinoma. Endocr J. 2008; 55:847–52.
Article
25. Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR, et al. Does familial nonmedullary thyroid cancer adversely affect survival? World J Surg. 2006; 30:787–93.
Article
26. Lee YM, Yoon JH, Yi O, Sung TY, Chung KW, Kim WB, et al. Familial history of nonmedullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma. J Surg Oncol. 2014; 109:168–73.
Article
27. Park YJ, Ahn HY, Choi HS, Kim KW, Park do J, Cho BY. The longterm outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 2012; 22:356–62.
Article
Full Text Links
  • KJES
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr